Description
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Principal Investigator
Recruitment Information
Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at (510) 204-5571.